ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1446

Is the Remission Achieved with Asdas, Basdaı a Real Remission? Should Ultrasound Be Added to the Parameters?

Emrah Koç1, Burak Okyar2, Sibel Bakırcı3, suade Özlem Badak2, Ali Nail Demir4, İsmail Uçar4, Gökhan Sargın5, Servet Yüce6 and Emine Duygu Ersözlü1, 1Adana City Training and Research Hospital, Adana, Turkey, 2Adana City Training and Research Hospital, Adana, 3Antalya training and research hospital, Antalya, Turkey, 4Mersin City Hospital, Mersin, Turkey, 5Aydin Adnan Menderes University, Aydın, Turkey, 6Şırnak Provincial Health Directorate Public Health Department, Şırnak, Turkey

Meeting: ACR Convergence 2024

Keywords: Ankylosing spondylitis (AS), biologic response modifiers, Disease Activity, Nonsteroidal antiinflammatory drugs (NSAIDs), Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The study aimed to evaluate changes in enthesis areas in ankylosing spondylitis patients in remission for at least six months, using either NSAIDs or biological agents. It aimed to assess the effects of these treatments on enthesis inflammation and potential disease modification.

Methods: In this cross-sectional study, 72 ankylosing spondylitis (AS) patients were divided into two groups: biological agent users and NSAID users. All patients underwent a clinical examination and ultrasound (US) scanning of 10 entheses by an experienced rheumatologist blinded to the physical examination findings. The US assessment evaluated the presence and severity of elementary lesions, including hypoechogenicity, thickening, power Doppler signals, erosions, enthesophytes, and calcifications. An inflammation score was calculated based on thickness increase, hypoechogenicity, and power Doppler scores, while a chronicity score was calculated from erosion, calcification, and enthesophyte scores. This study aimed to compare the US findings between the biological agent and NSAID user groups, providing insights into the structural and inflammatory changes in the entheses of AS patients receiving different treatment approaches.

Results: In our study, 98.6% of the quadriceps tendon, 61.1% of the proximal patellar tendon, 94.4% of the distal patellar tendon, 70.8% of the Achilles tendon and 70.8% of the plantar fascia had at least one of the six parameters.  The most common pathologies seen in all patients were hypoechogenicity, thickening, enthesopathy, and bone erosion (Table 1). In our study’s ASDAS assessment using CRP, the mean score of NSAID users was 2.06 ± 0.43, while the mean score of biological agent users was 1.85 ± 0.54. However, this difference was not statistically significant (p = 0.113). The mean inflammation score was 4.85, the mean tissue damage score was 6.44, and the total US enthesitis score was 11.24 in all patients (Table 2). Seven patients had a total enthesopathy score of > 20 points. The mean inflammation score was 14.71, the mean tissue damage score was 15.71, and the mean total enthesopathy score was 30.43 (Table 3). Treatment changes were made in five of the seven patients, taking into account their conditions and preferences. The mean inflammation score, tissue damage score, and total US enthesopathy scores improved by an average of five points in five patients within one month.

Conclusion: Our study can indicate that even more objective evaluations, such as ASDAS CRP, may be incomplete in assessing low disease activity or remission. In addition, similar US enthesopathy scores were measured in patients in remission using both NSAIDs and biological agents. ASDAS CRP < 2.1 and BASDAI < 4 in all patients receiving effective treatment. However, is the treatment adequate? Our US evaluation detected at least one finding in 98.6% of patients in the quadriceps tendon and 70.8% in the Achilles tendon. These results suggested that an objective assessment such as the US should be integrated into the total assessment. The favourable treatment modification results in five patients emphasised the importance of US findings and the necessity of combination therapies.

Supporting image 1

Ultrasonographic Findings of Our Patients (NSAID n:23, Biologic agent n:49, mean ± standard deviasion)

Supporting image 2

Demographic Characteristics and Clinical Parameters of Patients

Supporting image 3

Demographic characteristics and clinical parameters of patients with total US enthesopathy score ≥ 20 (n = 7)


Disclosures: E. Koç: None; B. Okyar: None; S. Bakırcı: None; s. Badak: None; A. Demir: None; İ. Uçar: None; G. Sargın: None; S. Yüce: None; E. Ersözlü: None.

To cite this abstract in AMA style:

Koç E, Okyar B, Bakırcı S, Badak s, Demir A, Uçar İ, Sargın G, Yüce S, Ersözlü E. Is the Remission Achieved with Asdas, Basdaı a Real Remission? Should Ultrasound Be Added to the Parameters? [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/is-the-remission-achieved-with-asdas-basdai-a-real-remission-should-ultrasound-be-added-to-the-parameters/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-the-remission-achieved-with-asdas-basdai-a-real-remission-should-ultrasound-be-added-to-the-parameters/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology